Novartis AG ranks slightly below the peer group median, with strong valuation and stability offset by very weak growth. Price action is lagging the structural profile — current market behavior is not yet confirming the structural position.
Peer-relative scores, weakest to strongest
Novartis is a global pharmaceutical company specializing in innovative medicines and generics. Its portfolio spans oncology, immunology, neuroscience, and cardiovascular therapies.
Novartis has a ROIC of 24.93% and an operating margin of 27.8%, positioning it among the sector’s most efficient capital allocators. However, the company’s growth profile is a structural headwind: revenue growth of just 2.2% year-over-year (peer score 36/100) shows a gap versus faster-growing competitors, resulting in mixed valuation support despite operational performance.
The internal picture is detailed. Novartis’s stability score of 93/100 confirms business resilience and a robust risk profile, and a 6.06% dividend yield indicates strong shareholder returns, but these strengths do not fully offset the impact of subpar revenue expansion. The recent Morgan Stanley upgrade and price target increase are positive signals, but the company’s growth rate lags sector leaders, limiting the scope for a clear rerating.
External context adds complexity. Analyst confidence, as reflected in the Morgan Stanley upgrade, and a Q1 2026 consensus revenue estimate of +4.87% YoY, support the execution story and suggest a possible inflection. However, the regulatory agreement on US drug pricing introduces uncertainty for long-term growth and margin mix—an issue not yet fully resolved and one that distinguishes Novartis from most peers.
Compared to AstraZeneca, ALK-Abelló, and Exelixis, Novartis stands out for its profitability and capital returns, but its growth profile is weaker than many peers. The regulatory pricing agreement, while partly idiosyncratic, further differentiates Novartis’s outlook and keeps its valuation support at the lower end of sector dynamics.
A more positive outlook would require revenue growth accelerating to at least peer median and regulatory headwinds proving manageable without margin erosion. Supporting improvement would include continued capital returns without compromising R&D. Until then, Novartis presents mixed valuation support and a growth profile under pressure.
Break down NOVN.SW's position across all dimensions with the full interactive tool.
This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.